Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies.

ABSTRACT:

Introduction

Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB).

Methods

A single site, randomized, double-blind, placebo-controlled study of the effects of oral bosutinib, 100 mg once daily for 12 weeks on primary safety and pharmacokinetics and secondary biomarker outcomes.

Results

Twenty-six participants were randomized and included male and female (12:1) in the bosutinib arm and all male (13) in the placebo arm. The average age was 72.9 ± 8.1 (year ± standard deviation). There were no serious adverse events and no dropouts. Bosutinib was measured in the cerebrospinal fluid (CSF) and inhibited Abelson. Bosutinib reduced CSF alpha-synuclein and dopamine catabolism.

Discussion

Bosutinib is safe and wel

SUBMITTER: Pagan FL 

PROVIDER: S-EPMC9157583 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature